search

Active clinical trials for "Hodgkin Disease"

Results 751-760 of 784

A Survey Exploring Health and Screening Tests in People Treated for Hodgkin Lymphoma

Hodgkin Lymphoma

A survey of health beliefs and cancer screening behaviour and intentions in Hodgkin lymphoma survivors

Completed5 enrollment criteria

Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced...

Malignant Neoplasm of BreastHodgkin Disease7 more

Identify the best combination of predictive variables that influence ionizing radiation dose and improved image quality through analysis and quantification of PET-CT images in simulators and patients.

Completed7 enrollment criteria

Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy

Hodgkin's Disease

The purpose of this study is to find out the impact Bleomycin-containing chemotherapy, given with or without chest radiation therapy, on patients' lung function over time.

Completed5 enrollment criteria

Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy...

Hodgkin's Lymphoma

The purpose of this study is to evaluate if radiation and chemotherapy treatment cause cardiac abnormalities among survivors of Hodgkin's lymphoma.

Completed5 enrollment criteria

Blood Samples to Evaluate Biomarkers of Donor Chimerism

LeukemiaHodgkins Disease2 more

We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants. We will look at the way the patient's body breaks down two drugs, fludarabine and mycophenolate mofetil, and how these two drugs affect the patient's body.

Completed6 enrollment criteria

Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers

Lung CancerOvarian Cancer3 more

You may have a type of cancer associated with "antineuronal antibodies" in your blood. Antibodies are substances made by the immune system. They are used by the body to fight infections and other diseases. Antineuronal antibodies are antibodies that react with nerve cells but they also react with some tumors. We believe that the immune system makes these antibodies to fight the cancer. In some patients with these antibodies, the tumor is smaller than in patients who have no antibodies. Sometimes, with a very strong antibody test, patients may develop neurologic problems such as weakness, numbness or memory loss. One purpose of this study is to determine if a patient with cancer and a positive antineuronal antibody blood test has a smaller tumor and responds better to treatment than a patient with cancer and a negative test. Another purpose of this study is to determine whether patients with a positive antibody test develop neurologic problems such as weakness, numbness or memory loss. We will measure your blood for several different kinds of antibodies in addition to antineuronal antibodies to determine if the presence of antibodies predicts "prognosis", i.e. smaller tumor and better response to treatment, or predicts the development of neurologic problems. No tissue samples are required for this study. However, if tissue or sputum is obtained by your oncologist for diagnostic purposes, we will ask your doctors or the pathology department to provide us with samples of these specimens. This will not involve any additional surgery or discomfort to you.

Completed3 enrollment criteria

Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease

Breast CancerHodgkin's Disease

The purpose of this study is to determine if the use of breast MRI in detecting breast malignancies in survivors of Hodgkin's disease is more successful than the traditional mammogram.

Completed9 enrollment criteria

Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

Hodgkin Lymphoma

To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Completed9 enrollment criteria

Follow Up of High Risk Hodgkin Lymphoma in First Complete Remission

Hodgkin LymphomaHigh Risk1 more

Cohort study enrolled high-risk Hodgkin Lymphoma patients in first relapse after induction therapy followed after remission either with a systemic imaging-based surveillance (Imaging cohort) or with standard clinical-based surveillance (standard cohort).

Completed3 enrollment criteria

FLT PET: A Pilot Study in Lymphoma Patients

Hodgkin's LymphomaNon-Hodgkin's Lymphoma

Background: Residual masses on follow-up surveillance imaging are frequently detected in paediatric patients with Hodgkin's lymphoma and non-Hodgkin's lymphoma. The residual mass may consist of inflammatory, fibrous or necrotic tissue, or it could represent residual tumor. In most cases, positron emission tomography (PET) with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) is useful for distinguishing tumor from fibrosis. However, FDG is not tumor-specific, and increased accumulation of the tracer may be seen in a variety of benign entities which can give rise to false-positive or equivocal FDG PET findings. Alternatively, the uptake of 3'-deoxy-3'-[fluorine-18]-fluorothymidine (FLT) reflects cellular proliferation, and may prove to be a reliable method in resolving equivocal FDG PET findings. Indeed, several studies have demonstrated that FLT can be safely administered to children, and in some cases be more useful than FDG PET in differentiating between infection or inflammation and malignancy. This study hypothesizes that FLT PET can be used as an adjunct imaging modality in paediatric lymphoma patients with equivocal interim or post-therapy FDG PET findings, and that this technique can provide additional diagnostic information which will be useful in distinguishing fibrotic or necrotic residual mass lesions from those that may be harbouring malignancy.

Completed7 enrollment criteria
1...757677...79

Need Help? Contact our team!


We'll reach out to this number within 24 hrs